# Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

> **NCT00473551** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Myeloma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mesna
- **RADIATION:** Radiation Treatment
- **PROCEDURE:** Stem Cell Transplantation (SCT)
- **DRUG:** Sirolimus
- **PROCEDURE:** Anti-third Party Cytolytic T-lymphocytes (CTL)

## Key facts

- **NCT ID:** NCT00473551
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual.
- **Last updated:** 2011-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00473551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00473551, "Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00473551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*